Apelinergic system as a promising target for myocardialdysfunction and shock

Cardiovascular disease and sepsis are two of the biggest public health problems in North America. Increasing evidence further suggests they are linked. Recent studies in human healthy volunteers and in chronic heart failure patients have highlighted the apelin system as a potential target for drug development. We therefore propose to fully validate pre-clinically the potential of apelin as a new target for cardiovascular disease and septic shock. By participating in cutting-edge research, the partner organization will gain further competitive advantage in the cardiovascular pharmacology market, and the joint publications will also increase the visibility of the company.

Faculty Supervisor:

Mannix Auger-Messier

Student:

Partner:

IPS Therapeutics Inc;Merck Canada Inc (Kirkland, QC);Université de Sherbrooke

Discipline:

Life Sciences

Sector:

Manufacturing; Professional, scientific and technical services

University:

Université de Sherbrooke

Program: